Authors: Edson Alves de Lima, Jr, Alexandre Abilio de Souza Teixeira , Luana Amorim Biondo, Tiego Aparecido Diniz, Loreana Sanches Silveira, Dario Coletti, Silvia Busquets Rius and José Cesar Rosa Neto.

Simple Summary: Doxorubicin is a chemotherapeutic agent that contributes to muscle wasting.

Based on the evidence that many cancer variants are associated with cachexia and that cancer patients are usually treated with chemotherapeutic agents, it is important to determine strategies to mitigate muscle atrophy. Muscle loss is a poor prognosis during cancer treatment, and exercise has emerged as a potential strategy utilized in this context. Once an ongoing regimen of chemotherapeutic treatment is not always possible, our results demonstrated that continuity of endurance exercise is a potential strategy that can be adopted when chemotherapy needs to be interrupted, minimizing the resumption of tumor growth and avoiding muscle loss.

Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699885/